Abstract
Although the development of vaccines for the prevention of arboviral diseases has been a priority in recent years, prevention strategies continue to depend on vector control. Risk maps at scales appropriate for these strategies can provide valuable information to assess entomological risk levels and guide actions. We used a spatio-temporal modeling approach to predict, at the local scale, the risk of homes potentially harboring Aedes aegypti larvae. The model used integrated larvae risk data collected in the field from September 2011 to February 2013, environmental data obtained from very high spatial resolution Pleiades imagery, and daily meteorological data, collected in the city of Matoury in French Guiana. Various environmental and meteorological conditions were identified as risk or protective factors for the presence of immature stages of Aedes aegypti in homes on a given date and used to produce dynamic maps with high spatial and temporal resolution. Aedes vector risk was modeled between 50 and 200 m, around houses, on a time scale of 3 to 5 days. The resulting model was extrapolated to other municipalities with the same characteristics of urbanization during the 2019-2020 dengue epidemic in French Guiana. This work represents a major opportunity to monitor the evolution of vector risk and constitutes information that could be particularly useful for public health authorities in charge of vector control.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Centre National d Etudes Spatiales-Terre solide, Ocean, Surfaces Continentales, Atmosphere fund (grant number CNES-TOSCA-4800000720). We acknowledge the European Regional Development Fund under EPI-ARBO grant agreement GY0008695.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Laboratory surveillance data collection issued from the national surveillance system and was approved by the Advisory Committee on Information Processing in Material research in the Field of Health (N 07.148) and was authorized by regulatory authorities (CNIL-N 1213498).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Epidemiological aggregated data belonging to French Public Health Agency (http://www.santepubliquefrance.fr/ <http://www.santepubliquefrance.fr/>) can be obtained contacting the scientific coordinator of Guyane Regional Epidemiology Unit of the French Public Health Agency (ars-guyane-cire@ars.sante.fr). All interested researchers can access the data by the same means the authors accessed them. Clinical data will not be made available according to the French CNIL recommandations (Commission Nationale Informatique et Libertes) that require specific authorizations to transfer data from one center to another. Requests for data transfer can be made to: CNIL, 8 rue Vivienne, CS 30223, 75083 Paris cedex 02, France. Tel: +33 (0)1.53.73.22.22; Fax: +33 (0)1.53.73.22.00.
